Crossmark

The Science and Clinical Evolution of Corneal Cross-Linking: Mechanism of Action, Ultra-Structural Changes, Clinical Indications, and Emerging Treatment Strategies

Crossref DOI link: https://doi.org/10.1007/s40123-026-01450-w

Published Online: 2026-07-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mazzotta, Cosimo

Lombardo, Marco https://orcid.org/0000-0001-8842-7102
Avitabile, Alessandro

Alessio, Giovanni

Borroni, Davide

D’Oria, Francesco https://orcid.org/0000-0002-5702-8595
License Information

Text and Data Mining valid from 2026-07-10

Version of Record valid from 2026-07-10
More Information

Article History

Received: 14 May 2026

Accepted: 19 June 2026

First Online: 10 July 2026

Declarations

:

: Cosimo Mazzotta is medical advisory board member of Emagine (Swiss); Marco Lombardo is co-inventor on issued patents (WO2017/130043, WO2020/261163 and WO2021009623A1) related to theranostics technology for treatment of corneal disorders and minor shareholder of Regensight (Italy); Giovanni Alessio, Alessandro Avitabile, Davide Borroni and Francesco D’Oria have nothing to disclose.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below